Stockscreener 앱 받기
0.6225
0.47%
0.0029
시간 외 거래:
.63
0.0075
+1.20%
전일 마감가:
$0.6196
열려 있는:
$0.622
하루 거래량:
65,699
Relative Volume:
0.89
시가총액:
$29.16M
수익:
$10.85M
순이익/손실:
$-51.31M
주가수익비율:
-0.8446
EPS:
-0.737
순현금흐름:
$-40.15M
1주 성능:
-11.07%
1개월 성능:
-25.91%
6개월 성능:
-59.58%
1년 성능:
-74.17%
1일 변동 폭
$0.609
$0.63
1주일 범위
$0.60
$0.71
52주 변동 폭
$0.60
$2.565
InspireMD Inc. Stock (NSPR) Company Profile
명칭
InspireMD Inc.
전화
972 3 6917691
주소
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
0.6225 | 32.79M | 10.85M | -51.31M | -40.15M | -0.737 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Maxim Group | Buy |
| 2016-01-07 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 개시 | Oppenheimer | Outperform |
InspireMD Inc. 주식(NSPR)의 최신 뉴스
InspireMD (NASDAQ:NSPR) Will Have To Spend Its Cash Wisely - Simply Wall Street
Form 4 InspireMD Inc For: 27 September By Investing.com - Investing.com UK
Form 4 InspireMD Inc For: 26 September By Investing.com - Investing.com Nigeria
Inspiremd Stock Price Forecast. Should You Buy NSPR? - StockInvest.us
Price performance - Yahoo Finance Singapore
Director Stuka Paul reports acquiring and disposing of two warrant series at InspireMD (NSPR). - Stock Titan
InspireMD (NSPR) director Gary S. Roubin acquired and disposed of warrants with different exercise prices. - Stock Titan
InspireMD (NSPR) director Michael Berman reports acquiring and disposing of warrants at two exercise prices. - Stock Titan
InspireMD amends certain Series J, Series K warrants - Medical Buyer
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
InspireMD (NASDAQ: NSPR) Revises Series J and K Warrants with $0.7674 Exercise Price and FDA-Linked Expiry by May 2028 - Kalkine Media
InspireMD Amends Warrants for Up to $11 Million Tied to FDA Approval - Minichart
InspireMD amends warrants tied to FDA approval timeline By Investing.com - Investing.com South Africa
InspireMD Amends Warrants to Support CGuard Prime Launch - TipRanks
InspireMD amends warrants tied to FDA approval timeline - Investing.com
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - The Manila Times
An anticipated FDA approval could open up $11 million for InspireMD's stroke-prevention device. - Stock Titan
InspireMD Q2FY26 Results: Net loss widens to $14.3M on recall impact - scanx.trade
Full Transcript: InspireMD Q2 2026 Earnings Call - Benzinga
NSPR: Innovative carotid stent technology is set to disrupt a rapidly expanding U.S. vascular market - TradingView
InspireMD announces inducement grants - Medical Buyer
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
InspireMD Inc. (NSPR) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
InspireMD Inc. (NSPR) Peer Comparison – Compare with Others - valueresearchonline.com
InspireMD Inc. Series B Warrants (NSPRZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Inc. Series B Warrants (NSPRZ) Peer Comparison – Compare with Others - Value Research
InspireMD Earnings Call: Recall Pain, Regulatory Potential - TipRanks
InspireMD Inc. Series B Warrants (NSPRZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD Inc. (NSPR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
InspireMD (NSPR) Drops 4.65% to $0.89 as Key Support at $0.85 Comes into FocusETF Creation Redemption - siam.in
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $3 - Moomoo
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate - Sci-Tech Today
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Cuts Target Price to $3 - Moomoo
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance - Stocktwits
InspireMD total revenue down 0.4% to USD 1,771,000 in Q2 2026 - Medical Buyer
Form 8K InspireMD Inc For: 17 August By Investing.com - Investing.com South Africa
InspireMD Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
InspireMD Q2 revenue holds at $1.8 million - grafa.com
InspireMD Releases Q2 2026 Financial Results - AlphaStreet
InspireMD, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares - Investing.com Nigeria
InspireMD Inc reports results for the quarter ended June 30Earnings Summary - TradingView
symbol__ Stock Quote Price and Forecast - CNN
InspireMD reports Q2 2026 revenue $1.77M, net loss $14.3M; cash & marketable securities $30.4M - TradingView
InspireMD Reports $1.77 Million Q2 Revenue and $14.32 Million Net Loss - Quiver Quantitative
InspireMD (NSPR) recall turns U.S. sales negative — and deepens quarterly loss - Stock Titan
InspireMD Q2 Operating Expenses USD 13.671 Mi - Moomoo
InspireMD Reports Second Quarter 2026 Financial Results - The Manila Times
InspireMD Inc. (NSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.26%
0.38%
자본화:
|
볼륨(24시간):